Quizartinib 17.7 mg Quizartinib tablets 17.7 mg x 14 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Prolonged QT interval, torsional ventricular tachycardia and sudden cardiac arrest: ECG and serum electrolyte levels are monitored. Reduce, discontinue or permanently discontinue LuciQuiza as appropriate.
• Embryo-fetal toxicity: LuciQuiza can cause fetal harm. Men of women of childbearing potential and of female partners of childbearing potential are advised to be aware of the potential risks to the fetus and to use effective contraception.

Medication risks

Adverse Reactions
The most common (> 20%) adverse reactions, including laboratory abnormalities, are lymphopenia, potassium decreased, albumin decreased, phosphorus decreased, alkaline phosphatase increased, magnesium decreased, febrile neutropenia, diarrhea, mucositis, nausea, calcium decreased, abdominal pain, sepsis, neutropenia, headache, creatine phosphokinase increased, vomiting, and upper respiratory tract infection.